AQR Capital Management
MRNA icon

AQR Capital Management’s Moderna MRNA Stock Holding History

AQR Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.6M Buy
479,141
+440,826
+1,151% +$22.8M 0.01% 960
2026
Q1 		$1.91M Buy
38,315
+26,305
+219% +$1.23M ﹤0.01% 2383
2025
Q4 		$354K Buy
+12,010
New +$326K ﹤0.01% 3098
2025
Q2 		– Sell
-15,253
Closed -$415K – 3354
2025
Q1 		$415K Buy
+15,253
New +$541K ﹤0.01% 2537
2024
Q4 		– Sell
-3,010
Closed -$201K – 2917
2024
Q3 		$201K Sell
3,010
-2,073
-41% -$190K ﹤0.01% 2567
2024
Q2 		$604K Buy
5,083
+1,232
+32% +$156K ﹤0.01% 1973
2024
Q1 		$410K Buy
3,851
+1,294
+51% +$130K ﹤0.01% 2029
2023
Q4 		$254K Buy
+2,557
New +$215K ﹤0.01% 2127
2023
Q3 		– Sell
-30,132
Closed -$3.66M – 2357
2023
Q2 		$3.66M Sell
30,132
-259,320
-90% -$34.6M 0.01% 1018
2023
Q1 		$44.2M Sell
289,452
-19,753
-6% -$3.26M 0.1% 252
2022
Q4 		$53.8M Sell
309,205
-285,180
-48% -$46.6M 0.12% 206
2022
Q3 		$70.3M Sell
594,385
-690,182
-54% -$105M 0.17% 138
2022
Q2 		$177M Sell
1,284,567
-80,803
-6% -$11.5M 0.4% 39
2022
Q1 		$235M Buy
1,365,370
+847,320
+164% +$143M 0.45% 37
2021
Q4 		$130M Buy
518,050
+79,961
+18% +$23.4M 0.23% 103
2021
Q3 		$166M Sell
438,089
-247,604
-36% -$91.3M 0.31% 70
2021
Q2 		$161M Sell
685,693
-281,604
-29% -$50.3M 0.28% 81
2021
Q1 		$122M Buy
967,297
+825,570
+583% +$120M 0.2% 119
2020
Q4 		$14.8M Buy
141,727
+66,122
+87% +$6.69M 0.03% 516
2020
Q3 		$5.35M Buy
75,605
+17,472
+30% +$1.22M 0.01% 753
2020
Q2 		$3.66M Buy
58,133
+48,240
+488% +$2.64M 0.01% 898
2020
Q1 		$293K Buy
+9,893
New +$228K ﹤0.01% 1771

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

AQR Capital Management's MRNA Position: Q2 2026 in Review

AQR Capital Management increased its Moderna (MRNA) stake by 1,151% in Q2 2026, buying an estimated $22.8M and bringing the position to 479,141 shares worth $33.6M. The position accounts for 0.01% of the portfolio, ranked #960.

AQR Capital Management first reported a position in MRNA in Q1 2020 and has held it in 22 quarters since. The position peaked at $235M in Q1 2022. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • AQR Capital Management held 479,141 shares of Moderna worth $33.6M as of Q2 2026.
  • AQR Capital Management bought 440,826 Moderna shares in Q2 2026, an estimated $22.8M.
  • Moderna made up 0.01% of AQR Capital Management's portfolio in Q2 2026, its #960 holding.
  • AQR Capital Management first reported a position in Moderna in Q1 2020 and has held it in 22 quarters since.
  • AQR Capital Management's Moderna position peaked at $235M in Q1 2022.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.